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Abstract Statins (hydroxymethylglutaryl-coenzyme-A
reductase inhibitors) are first-line agents for the manage-
ment of hyperlipidemia in patients at high risk of cardio-
vascular (CV) events, and are the most commonly
prescribed CV drugs worldwide. Although safe and gen-
erally well tolerated, there is growing evidence to suggest
that statins are associated with an elevated occurrence of
new-onset diabetes mellitus (DM). Recent experimental
and clinical data have prompted the US Food and Drug
Administration to add information to statin labels regarding
the increased risk of development of type 2 DM. The main
purpose of this review is to critically discuss the clinical
evidence regarding the association of statin use with new-
onset DM, the CV benefit/risk ratio with statins, and the
rationale for individualized statin therapy.
1 Introduction
Statins (hydroxymethylglutaryl-coenzyme-A [HMG-CoA]
reductase inhibitors) are the most commonly prescribed
cardiovascular (CV) drugs worldwide [1].
Although safe and generally well tolerated, emerging
data have suggested that statins are associated with an
increased rate of new-onset diabetes mellitus (DM). These
recent concerns have prompted the US Food and Drug
Administration (FDA) to add information to statin labels
about the increased risk of raised blood sugar levels and
development of type 2 DM [2]. The present article aims to
critically discuss (i) the mechanisms and clinical evidence
linking statins to DM onset, (ii) the impact of different
statin types or doses on DM, and (iii) the rationale of tai-
lored statin therapy based on different clinical scenarios,
including the patient’s CV and metabolic risk profile.
2 Statins and New-Onset Diabetes Mellitus (DM):
is there a Link?
Although the precise pathway responsible for DM onset
with statin therapy is still unknown, there are several
postulated mechanisms, some of which can be mentioned.
Statins can down-regulate the pancreatic b-cell function
and insulin secretion via inhibition of glucose-induced
Ca2? signaling pathways [3].
Insulin release may also be impaired by the decreased
amount of adenosine triphosphate (ATP), a result of statin
suppression of the ubiquinone biosynthesis [4], which
ultimately causes delayed production of ATP. It has also
been hypothesized that statins may promote b-cell apop-
tosis, enhancing nitric oxide production by the endothelium
[5]. Even though statins do not exert a class effect on
insulin sensitivity, some inter-class differences have been
observed.
Another suggested pathway influencing insulin sensi-
tivity in statin-treated patients is the impact on insulin-
responsive glucose transporter type (GLUT)-4. The inhi-
bition of HMG-CoA reductase promoted by statins has a
suppressing effect on isoprenoids synthesis, in turn result-
ing in decreased GLUT-4 expression and eventually to
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impaired glucose transport. Two studies [6, 7] showed that
this mechanism is distinctive for atorvastatin and lova-
statin; in contrast, the depression of adipocyte maturation
was not reported with pravastatin intake. A further pro-
posed mechanism lies in the effect on the adiponectin
metabolism. Adiponectin is a hormone that modulates
some metabolic processes, including glucose regulation.
Among its actions, it decreases gluconeogenesis and
increases glucose uptake; high levels of adiponectin have
been associated with a reduction in the risk of developing
type 2 DM in a prospective study [8]. Simvastatin has been
reported to significantly reduce adiponectin levels and
insulin sensitivity in hypercholesterolemic patients [9].
It has also been hypothesized that lipophilic and
hydrophilic statins have different effects on adiponectin
and insulin resistance. Pravastatin, a hydrophilic statin,
increases adiponectin levels and insulin sensitivity [10]. An
experimental study recently performed by Koh and col-
leagues [11], found that rosuvastatin, which is more potent
and less hydrophilic, than pravastatin is associated with
adverse metabolic effects, including increases in insulin
resistance and glycosylated hemoglobin levels. Conversely,
pravastatin proved to be safe by decreasing these two
parameters; in the current study, rosuvastatin also
decreased plasma adiponectin levels.
3 Statins and New-Onset DM
3.1 Recent Evidence
Several recent randomized controlled trials (RCTs) have
yielded conflicting results regarding the induction of DM
by statins. The WOSCOPS (West of Scotland Coronary
Prevention Study) trial showed that the incidence of DM
was 30 % lower in male patients receiving pravastatin
40 mg/day than in those receiving placebo [12]. However,
this was not observed with atorvastatin 10 mg/day in the
ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes
Trial-Lipid-Lowering Arm) trial [13], nor with simvastatin
40 mg/day in the HPS (Heart Protection Study) trial [14].
The JUPITER (Justification for the Use of Statins in Pri-
mary Prevention: An Intervention Trial Evaluating Rosu-
vastatin) trial [15], using rosuvastatin 20 mg/day in
patients with elevated levels of C-reactive protein (CRP),
was stopped early when an interim analysis found a 44 %
lower incidence of the primary endpoint. However, during
the study, there was a 26 % higher incidence of DM.
Rajpathak et al. [16] performed a meta-analysis of five
trials involving 51,619 participants, among whom 1,943
developed DM. A small but significant increase in DM risk
was found: relative risk (RR) 1.13; 95 % confidence
interval (CI) 1.03–1.23. The authors concluded that this
finding may be related to statin use. In their initial analysis,
they excluded WOSCOPS, describing it as hypothesis-
generating; with the incorporation of the WOSCOPS trial,
the increase in DM risk was no longer significant.
Sattar and colleagues [17], in a larger meta-analysis
published in 2010, included the 13 major statin trials
(91,140 patients); each trial had more than 1,000 partici-
pants and more than 1 year of follow-up. However, the
longest follow-up did not reach 5 years, new DM was
observed in 2,226 (4.89 %) of the statin recipients and in
2,052 (4.5 %) of the placebo recipients (odds ratio [OR]
1.09; 95 % CI 1.02–1.17).
Two of the arguments called to critically discuss this
evidence can be cited: (i) the single studies were not
designed and powered to primarily address DM as an
endpoint and maximum follow-up did not exceed 5 years;
(ii) the definition of DM varied among the trials, often
derived from non-standardized criteria, and new-onset DM
was usually not rigorously screened for. Combining both
these elements, it is possible to conclude that we may even
have underestimated the dimension of the problem.
3.2 Impact of Different Types and Doses of Statin
In recent years, the question has been raised as to whether or
not the type of statin and the intensity of dose contributes to
the conflicting results observed in RCTs and meta-analyses.
Carter and colleagues [18] recently conducted a popu-
lation-based study, showing in a real-world setting that,
compared with pravastatin (the reference drug in all anal-
yses), there was an increased risk of incident DM with
atorvastatin (adjusted hazard ratio [HR] 1.22; 95 % CI
1.15–1.29), rosuvastatin (HR 1.18, 95 % CI 1.10–1.26),
and simvastatin (HR 1.10, 95 % CI 1.04–1.17). The authors
stated that the risk associated with rosuvastatin may be
relevant to the dose of the drug. However, after the rosu-
vastatin dose was reduced, the statistical outcome was non-
significant, suggesting a potential impact of indication or
prescription bias that it was not possible to exclude because
of the observational nature of the study.
Moreover, a published meta-analysis of five randomized
trials (N = 32,752) [19] found that the use of intensive-
dose statin therapy compared with moderate-dose statin
therapy was associated with a higher incidence of new-
onset DM. In this paper, DM developed in 1,449 (8.8 %) of
the intensive-therapy group and 1,300 (8.0 %) of the
moderate-therapy group (OR 1.12, 95 % CI 1.04–1.22). In
contrast, incident CV disease occurred in 3,134 (19.1 %) of
the intensive-therapy group and 3,550 (21.7 %) of the
moderate-therapy group (OR 0.84, 95 % CI 0.75–0.94).
Therefore, there was a 0.8 % absolute increase in DM
cases on high-dose statins and a 2.6 % absolute reduction
in adverse CV events.
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Recently, Navarese and colleagues [20] published the
largest and most comprehensive meta-analysis so far,
comparing rates of new-onset DM among different types
and doses of statins. The main findings, derived from a
population of 113,394 patients, were as follows: (i) there
was a gradient in the risk for new-onset DM across dif-
ferent types and doses of statins (Fig. 1a); (ii) pravastatin
therapy was numerically associated with the lowest OR of
new-onset DM compared with placebo (OR 1.07, 95 %
credible interval 0.86–1.30); in contrast, treatment with
rosuvastatin was numerically associated with a 25 %
increased risk of DM compared with placebo (OR 1.25,
95 % credible interval 0.82–1.90); (iii) the cumulative
probabilities indicated that high-dose pravastatin had the
highest probability of being the safest treatment in terms of
new-onset DM, with rosuvastatin and simvastatin per-
forming least well in this ranking; (iv) compared with
placebo, high-dose pravastatin provided the most robust
safety profile compared with the other high-dose statins;
(v) the findings were confirmed with moderate doses of
statins (Fig. 1b); and (vi) for each statin, increased doses
carried a numerically higher risk for new-onset DM than
moderate doses. As an additional datum, by meta-regres-
sion analysis, the risk for developing DM was not found to
be influenced by the different abilities of statins to reduce
cholesterol. On the basis of these findings, this meta-ana-
lysis supports the investigation of molecule-dependent
mechanisms responsible for DM onset (Table 1).
3.3 Clinical Benefits versus DM Risk with Statins
CV disease (CVD) is the major cause of mortality and one
of the most important causes of morbidity in the world.
Owing to the major role of low-density lipoprotein (LDL)
cholesterol as a modifiable risk factor, over the years,
several international guidelines have recommended the
Fig. 1 Individual OR with
related 95 % CrIs for new-onset
DM comparing intensive (a) or
moderate (b) statin doses and
placebo. Adapted from
Navarese et al. [20]. Atorv
atorvastatin, CrI credible
interval, DM diabetes mellitus,
OR odds ratio, Prav pravastatin,
Rosuv rosuvastatin, Simv
simvastatin
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achievement of LDL goals in patients with different CV risk
profiles (Table 2). Indeed, statins have largely been dem-
onstrated in several landmark trials and meta-analyses
[21–23] to be beneficial in secondary prevention of CV
events and primary prevention in high-risk patients. Sattar
and colleagues [17] estimated that statin treatment is asso-
ciated with 5.4 fewer deaths from coronary heart disease
and cases of nonfatal myocardial infarction per 255 patients
treated over 4 years for each 1-mmol/L (39 mg/dL)
reduction in LDL cholesterol compared with controls. In
contrast, there was a risk of developing one additional case
of DM for 255 patients treated with statins. In the meta-
analysis by Preiss et al. [19], 6.5 CV events were prevented
in the intensive-dose statin group per 1,000 patient-years;
this in turn translates into a number needed to treat
(NNT) of 155 for CV events and a number needed to harm
(NNH) of 498 for new-onset DM. In secondary prevention,
benefits of statin therapy clearly outweigh DM risk.
Primary prevention in patients with no previous CVD is
another important scenario not fully exploited in low-risk
patients, for whom statin therapy is increasingly used for
vascular prevention; indeed, there has been controversy as
to whether the absolute benefit of treatment outweighs the
risk of developing DM.
Importantly, a meta-analysis by Taylor et al. [24] found
that statins in the primary prevention of CVD have no
effects on significant reduction in all-cause mortality; this
meta-analysis showed that a mortality relative risk reduc-
tion (RRR) of 17 % was observed with statin treatment.
However, they concluded that there is not enough evidence
to recommend the widespread use of statins in the primary
prevention of heart disease. The authors of this meta-ana-
lysis noticed that the absolute benefits were rather small—
1,000 people have to be treated for 1 year to prevent one
death. The advantages of statin therapy therefore may
become very small when used among people at low
absolute risk, and a higher NNT to gain some benefit.
Therefore, it is still uncertain where exactly the point lies
beyond which the beneficial and protective CV actions of
statins begin to outweigh the diabetogenic risk in primary
prevention. The most recent individual-data meta-analysis
of CTT (Cholesterol Treatment Trialists) Collaborators
[25] states that even patients with low risk for CV events
gain benefit from cholesterol-lowering treatment. In their
study, each 1 mmol/L reduction in LDL cholesterol pro-
duced an absolute reduction in major vascular events of
about 11 per 1,000 patients treated over 5 years. Intrigu-
ingly, age, sex, baseline LDL cholesterol, previous vascu-
lar disease, and vascular and all-cause mortality had little
impact on the volume of major vascular event risk
reduction.
In primary prevention with statins, the magnitude of the
increased risk of incident DM is estimated to be [50-fold
smaller than the absolute CV benefit: approximately 0.2 per
Table 1 Effect of different statins on glucose metabolism
Effect on glucose metabolism Statin Main observation References
Decreased insulin secretion Atorvastatin HMG-CoA inhibition/cytotoxicity [30]
Simvastatin
Simvastatin Blocks L-type Ca2? channels [35]
Decreased insulin sensitivity Atorvastatin Reduction in insulin sensitivity without reduction in insulin secretion [31]
Atorvastatin Inhibition of isoprenoid synthesis/GLUT-4 expression [6, 7]
Lovastatin [7, 33]
Simvastatin Decreased adiponectin secretion [10]
Atorvastatin [32]
Rosuvastatin [36]
Rosuvastatin HMG-CoA reductase inhibition via enhanced binding [37]
Insulin sensitization [38]
Increased insulin sensitivity Atorvastatin Induction of insulin sensitivity in lean and fatty rats [33]
Pravastatin Increased adiponectin secretion [10, 34, 40, 41]
Rosuvastatin Normalizes elevated expression of PTP-1B [38]
Up-regulated expression of IRS-2, P-IRS-2, AKT, P-AKT, and GLUT4 [39]
No effect on glucose metabolism Pravastatin No effect on L-type Ca2? channels [35]
No HMG-CoA inhibition/cytotoxicity [30]
Does not inhibit isoprenoid synthesis/GLUT-4 expression [6]
No effect on adiponectin secretion [42, 43]
AKT protein kinase B, GLUT-4 glucose transporter type 4, HMG-CoA hydroxmethylglutaryl-coenzyme-A, IRS-2 insulin receptor substrate 2,
P-AKT phosphorylated protein kinase B, P-IRS-2 phosphorylated insulin receptor substrate 2, PTP-1B protein phosphatase-1B
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1,000 individuals develop DM and 11 major CV events are
prevented over a 5-year period. However, even in the
lowest-risk group studied, the average baseline LDL cho-
lesterol level was greater than 130 mg/dL. Additionally,
among the low-risk population, no significant benefit was
observed with statin therapy with respect to CV mortality
as a single endpoint; these points make it reasonable to be
more cautious when treating these patients with statins.
Therefore, any decision to use statins in primary prevention
should be made in light of the assessment of the patient’s
overall CV risk and metabolic profile.
3.4 Rationale for Tailored Statin Therapy
To address the rationale for tailored statin therapy is crucial
to underline the definition of tailored therapy; this is a
strategy aimed to provide the right drug, the right dose, to
the right patient and in the right time.
What is the rationale for individualized statin therapy?
Different arguments are in favor of a more balanced tai-
lored statin therapy based on clinical judgments, the
patient’s CV and metabolic risk profile, and the type and
dose of statin used.
Table 2 Guidelines on low-density lipoprotein goal with regards to cardiovascular risk
Guidelines Year Risk category LDL goal (mg/dL)
NCEP ATP III 2004 High risk: CHD or CHD risk equivalent (e.g., DM or 10-year FRS
[20 %)
\100
\70 optional
Moderately high risk: C2 risk factors (10-year FRS 10–20 %) \130
\100 optional
Moderate risk: C2 risk factors (10-year FRS \10 %) \130
Low risk: 1 or no risk factor \160
ADA/ACC Consensus
Report
2008 Highest risk: CVD or diabetes plus additional major CVD risk factors \70
High risk: No DM or known CVD but C2 major CVD risk factors, or
DM but no other major CVD risk factors
\100
AHA/ACCF Guideline
on Secondary
Prevention
2011 CHD or other atherosclerotic vascular disease C30 % reduction
\100
CHD at very high risk \70 reasonable
NLA Expert Panel on
FH Clinical Guidance
2011 Adults (aged C20 years) with FHc and LDL-C C190 mg/dL or non–
HDL-C C220 mg/dL
C50 % reduction
Children (aged C8 years) with FHc and LDL-C C190 mg/dL or non–
HDL-C C220 mg/dL
C50 % reduction
or \130
ESC/EAS 2011 Very high CV risk (established CVD, DM type 2, DM type 1 with organ
damage, moderate to severe CKD or SCORE level C10 %)
\70
And/or C50 % reduction, when
the target level can not be
reached
High CV risk (markedly elevated single risk factors, a SCORE level C5
to \10 %)
\100
Moderate risk (SCORE level [1 to B5 %) \115
AACE 2012 Very high risk established or recent hospitalization for coronary, carotid
or peripheral vascular disease; DM with C1 additional risk factor(s)
\70
High risk C2 major risk factors and FRS [20 %; CHD risk equivalent
(carotid artery disease, abdominal aortic aneurysm, peripheral arterial
disease, DM)
\100
Moderately high risk C2 major risk factors and FRS 10–20 % \130
Moderate risk C2 major risk factors and FRS \10 % \130
Low risk B1 risk factor \160
ADA 2013 Individuals with DM and without overt CVD \100
Individuals with DM and with overt CVD \70
AACE American Association of Clinical Endocrinologists, ADA/ACC American Diabetes Association/American College of Cardiology, AHA/
ACCF American Heart Association/American College of Cardiology Foundation, CHD coronary heart disease, CKD chronic kidney disease, CV
cardiovascular, CVD CV disease, DM diabetes mellitus, EAS European Atherosclerosis Society, ESC European Society of Cardiology, FH
familial hypercholesterolemia, FRS Framingham risk score, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cho-
lesterol, NCEP ATP National Cholesterol Education Program Adult Treatment Panel, NLA National Lipid Association
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With regard to clinical setting and the patient’s risk
profile, as discussed previously, the benefit/risk assessment
should be individualized based on the clinical scenario
(primary/secondary prevention). In secondary prevention,
the benefits of statin therapy clearly outweigh the risks of
DM.
In primary prevention of low-risk patients, the cost
effectiveness of such a strategy is less clear and has to be
balanced against the risk of ‘overmedicating’ the general
population.
A recent study [26] compared the incidence of new-
onset DM with CV risk reduction among 15,056 patients
with coronary heart disease or a history of myocardial
infarction but without DM at baseline in the TNT (Treating
to New Targets) IDEAL (Incremental Decrease in End-
points Through Aggressive Lipid Lowering) studies.
Patients in these trials were randomly assigned to high- or
low-dose statin (80 mg atorvastatin vs. 10 mg atorvastatin
or 20–40 mg simvastatin). In particular, the investigators
looked for differences in patients with 0–1 risk factors for
new-onset DM at baseline compared with those who had
2–4 risk factors (i.e., fasting blood glucose [100 mg/dL,
history of hypertension, body mass index [30 kg/m2, and
fasting triglycerides).
Among the patients with 0–1 risk factors at baseline,
DM developed in 142 of 4,407 patients in the high-statin
dose group and in 148 of 4,418 patients in the low-dose
groups. Meanwhile, CV events were significantly lower in
the high-dose group. Among the patients with 2–4 risk
factors, DM developed in 448 of 3,128 patients in the high-
dose group and in 368 of 3,103 patients in the lower-dose
groups. However, the risk for CV events was 18 % lower in
the high-dose group. The main finding of this analysis was
that the increase in risk of DM was largest in patients who
also received the largest risk reduction for CV events with
statin therapy. However, it must be noted that the patients
enrolled in the trials were in a ‘secondary prevention’
setting, already presenting at baseline with coronary artery
disease and/or previous myocardial infarction. Importantly,
the current study also suggests an increased risk of devel-
oping DM for patients who are at high metabolic risk.
Within this framework, tailoring therapy based on the
specific type and dose of statin might play a crucial role;
different types and doses of statin vary in their power to
reduce cholesterol as well as in their ‘diabetogenic’
potential.
Physicians should now be aware that there is a gradient
in the risk of new-onset DM across different types and
doses of statins. Identifying patients who would benefit
more from less diabetogenic statin types or regimens could
help optimize the treatment by providing the highest ben-
efit achievable while reducing the number of patients
developing DM under statin therapy.
Based on our findings, pravastatin could be the right
match for hyperlipidemic patients at low CV risk. Indeed,
despite its lower potential to lower LDL cholesterol con-
centrations, it seems to be the least diabetogenic statin
currently available on the market. Although marginalized
Fig. 2 Individualized algorithm
of treatment with statins, based
on clinical scenario and
patient’s risk profile. ACS acute
coronary syndrome, CAD
coronary artery disease
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by newer, more powerful, and more advertised statins,
pravastatin could serve as a valuable alternative, especially
for patients with a predisposition for DM; the lower price
of the drug (being now available as a generic) could also
increase the cost effectiveness of medicating the low-risk
population.
Nevertheless, it is crucial to remember that statins can-
not account for all new cases of DM diagnosed during
hypolipidemic therapy. Waters et al. [26] support this
concept, showing that the hazard of developing new-onset
DM is directly connected with already existing DM risk
factors.
3.5 Proposed Individualized Algorithm of Treatment
We propose an individualized and simplified algorithm of
statin treatment based on the current evidence (Fig. 2). The
present algorithm does not aim to replace any guideline
recommendations based on cholesterol levels; the focus of
this scheme is the clinical scenario and patient risk that can
orient towards the choice of a specific type and dose of
statin.
The benefits of statins outweigh the increased risk of
DM in people with CVD or at moderate to high risk of
CVD. In such patients, a powerful statin like rosuvastatin
or atorvastatin should be recommended. Individuals with
high CV risk (10-year risk [20 %, according to the Fra-
mingham risk score) or existing CVD should receive statin
therapy as indicated. Individuals with moderate CV risk
(C2 risk factors, 10-year risk B20 %) should also be pre-
scribed a statin. In high-risk subgroups such as after an
episode of acute coronary syndrome (ACS), high doses of a
powerful statin like rosuvastatin or atorvastatin are highly
recommended.
The potentially raised DM risk exceeding benefits
should be particularly considered in individuals with low
CV risk (0–1 risk factors). Prior to initiation of statin
therapy, screening for risk factors of DM and metabolic
syndrome may help identify patients at high risk of DM
requiring closer monitoring. According to the recent evi-
dence, pravastatin can be the statin of choice in such
populations. As discussed previously, there is thus far a
lack of conclusive evidence in favor of statin administra-
tion in low-risk patients.
In the present algorithm, the patient population was
divided into two treatment groups, according to the clinical
setting at presentation (primary and secondary prevention).
In the secondary prevention setting and high risk popula-
tion, such as patients after ACS or stroke, we suggest,
based on the current evidence, treatment with intensive
doses of such a statin as atorvastatin 80 mg [27, 28].
However, in the case of patients with stable coronary artery
disease, lower doses such as atorvastatin 10–20 mg,
rosuvastatin 10–20 mg, or simvastatin 40 mg would be a
reasonable option. In the primary prevention group,
patients can be stratified according to the number of DM
risk factors; in the higher risk subset, constant glycemic
control is advised, together with statin therapy at moderate
doses, such as pravastatin 40 mg [12]. The last analysed
category is that of patients with one or no risk factors for
new-onset DM; moderate doses might be used in such
patients. An alternative option is to only monitor glucose
more closely, avoiding the prescription of statins, although
there is less robust evidence in this regard. Further RCTs
are certainly needed to definitively confirm the clinical
impact of tailored statin treatment based on risk scenario
and the patient’s risk profile.
3.6 Future Research
As recommendations for the future, it is essential to con-
duct long-term prospective RCTs and cost-effectiveness
analyses to address the benefit/risk ratio of statins, espe-
cially in the field of primary prevention. Indeed, the cost
effectiveness of such a strategy is unclear in these low-risk
patients and has to be balanced against the risk of ‘over-
medicating’ the general population. Additional studies are
also warranted to determine the mechanism of statin-
induced DM, the time to the onset of DM, and the degree of
hyperglycemia. Finally, the question of why statins cause
DM must be answered. A genomic stratification might
further identify patients at risk for this important and
chronic side effect, similar to the variability in treatment
response found based on the pharmacogenomic profile
[29].
4 Conclusions
Medicine is a dynamic field. According to emerging data
on statin therapy, ‘one size does not fit all’ with respect to
DM: each statin is associated with a specific DM risk
profile. A potential tailored statin treatment based on the
patient’s CV and metabolic risk profile might emerge as the
safest therapeutic approach. Future trials with adequate
follow-up of more than 5 years and designed to assess the
benefit/risk ratio of a specific statin will further refine the
basis of this strategy.
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